---
title: "MRI Radiomic Biomarkers Improve Prognosis for Lung Cancer Brain Metastases"
id: "medrxiv-16-mri-biomarkers-for-brain-metastases-in-lung-cancer-using-machine-learning"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-16-mri-biomarkers-for-brain-metastases-in-lung-cancer-using-machine-learning"
content_type: "clinical_feed_article"
specialty: "Oncology"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.10.12.26365323v1?rss=1"
published_at: "2026-10-13T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# MRI Radiomic Biomarkers Improve Prognosis for Lung Cancer Brain Metastases
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-16-mri-biomarkers-for-brain-metastases-in-lung-cancer-using-machine-learning
- **Specialty:** [Oncology](https://medichelpline.com/clinical-feed/oncology.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.10.12.26365323v1?rss=1)
- **Published At:** 2026-10-13T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- Retrospective cohort of 103 patients with **lung cancer** brain metastases, each with preoperative T1-contrast and FLAIR MRI and matched histopathology. The study combined imaging and clinical data to build survival and progression models. - Radiomic features were extracted from T1-weighted contrast-enhanced (T1CE) and T2 FLAIR sequences; the source did not report specific feature lists or exact extraction parameters in detail. - Modeling frameworks included Cox proportional hazards, random survival forest, and a neural network survival model (reported as **DeepSurv**); investigators trained models for overall survival (OS), CNS progression, and leptomeningeal (LM) progression. - Combined clinical-imaging models outperformed clinical-only models across frameworks. The combined **DeepSurv** model achieved the highest concordance index for OS (0.728) as reported by the authors. - Risk groups produced by the best model per endpoint showed significant OS separation (median 26.7 vs. 9.1 months, p < 0.001) and differed for LM progression (p = 0.003), but did not differ for CNS progression. - Imaging-only risk groups did not differ on measured clinical variables; however, high-risk imaging-only patients had lower rates of tumor-infiltrating lymphocytes (46% vs. 77%, p = 0.010) and lower PD-L1 expression ≥50% (10% vs. 32%, p = 0.049), linking radiomic signals to the tumor immune microenvironment. - Data availability: preoperative MRI, radiomic feature files, segmentation masks, clinical metadata, and digitized pathology are publicly accessible via The Cancer Imaging Archive (TCIA) per the authors. - The source lists IRB approval (Yale University protocol 2000027592) with waiver of consent and declares no competing interests. The preprint did not report detailed model hyperparameters, exact radiomic feature names, or external validation beyond the reported cohort.
## Clinical Analysis & Structured Key Points
MRI Biomarkers for Brain Metastases in Lung Cancer Using Machine Learning | medRxiv Skip to main content MRI Biomarkers for Brain Metastases in Lung Cancer Using Machine Learning Saahil Chadha , Durga V. Sritharan , Rohan Sharma , Darin Dolezal , Sampada Chande , Gregory Breuer , Daniel Fu , Arihan Gupta , Jahid Omar Hossain , Anand Srinivasan , David Weiss , Veronica L. Chiang , Don X. Nguyen , Sanjay Aneja doi: https://doi.org/10.64898/2026.10.12.26365323 Saahil Chadha Yale School of Medicine Find this author on Google Scholar Find this author on PubMed Search for this author on this site Durga V. Sritharan Yale School of Medicine Find this author on Google Scholar Find this author on PubMed Search for this author on this site Rohan Sharma Yale School of Medicine Find this author on Google Scholar Find this author on PubMed Search for this author on this site Darin Dolezal Yale School of Medicine Find this author on Google Scholar Find this author on PubMed Search for this author on this site Sampada Chande Yale School of Medicine Find this author on Google Scholar Find this author on PubMed Search for this author on this site Gregory Breuer Yale School of Medicine Find this author on Google Scholar Find this author on PubMed Search for this author on this site Daniel Fu Yale School of Medicine Find this author on Google Scholar Find this author on PubMed Search for this author on this site Arihan Gupta Yale School of Medicine Find this author on Google Scholar Find this author on PubMed Search for this author on this site Jahid Omar Hossain Yale School of Medicine Find this author on Google Scholar Find this author on PubMed Search for this author on this site Anand Srinivasan Yale School of Medicine Find this author on Google Scholar Find this author on PubMed Search for this author on this site David Weiss Yale School of Medicine Find this author on Google Scholar Find this author on PubMed Search for this author on this site Veronica L. Chiang Yale School of Medicine Find this author on Google Scholar Find this author on PubMed Search for this author on this site Don X. Nguyen Yale School of Medicine Find this author on Google Scholar Find this author on PubMed Search for this author on this site Sanjay Aneja Yale School of Medicine Find this author on Google Scholar Find this author on PubMed Search for this author on this site For correspondence: sanjay.aneja{at}yale.edu Abstract Info/History Metrics Supplementary material Data/Code Preview PDF Abstract Purpose: Existing prognostic models for brain metastases from lung cancer rely on clinical variables and do not capture the biological heterogeneity of host or tumor factors underlying survival outcomes. We evaluated whether MRI-derived radiomic biomarkers improve prognostic stratification beyond clinical variables. We also investigated their biological correlates using matched histopathology. Experimental Design: This retrospective study included 103 patients with brain metastases from lung cancer and matched pre-operative MRI and histopathology. Radiomic features from T1-weighted contrast-enhanced and T2-weighted fluid-attenuated inversion recovery sequences were combined with clinical variables to train Cox proportional hazards, random survival forest, and DeepSurv models for overall survival (OS), CNS progression, and leptomeningeal (LM) progression. Risk groups from an imaging-only model were compared for clinical and histopathologic differences. Results: Imaging features improved prognostic performance beyond clinical variables across all modeling frameworks, with the combined clinical-imaging DeepSurv model achieving the highest concordance index for OS (0.728). Risk groups from the best-performing model for each endpoint differed significantly in OS (median 26.7 vs. 9.1 months, p < 0.001) and LM progression (p = 0.003), but not in CNS progression. Imaging-only risk groups did not differ significantly in any clinical variable, but high-risk patients were less likely to have tumor-infiltrating lymphocytes (46% vs. 77%, p = 0.010) and PD-L1 expression ≥ 50% (10% vs. 32%, p = 0.049). Conclusions: MRI radiomic biomarkers provide prognostic information beyond established clinical variables in lung cancer brain metastases and correspond to features of the tumor immune microenvironment, supporting their potential to refine risk stratification. Competing Interest Statement The authors have declared no competing interest. Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: The Institutional Review Board of Yale University (protocol 2000027592) gave ethical approval for this work, with a waiver of informed consent. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes Data Availability Pre-operative MRI sequences (T1CE and FLAIR), radiomic feature files, segmentation masks, clinical metadata, and digitized pathology images are publicly accessible through The Cancer Imaging Archive (TCIA) (https://doi.org/10.7937/k0sm-y874). Additional data may be made available upon reasonable request to the corresponding author, subject to Yale University Institutional Review Board and data use agreement requirements. https://doi.org/10.7937/k0sm-y874 Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. Back to top Previous Next Posted October 13, 2026. Download PDF Supplementary Material Data/Code Email Thank you for your interest in spreading the word about medRxiv. NOTE: Your email address is requested solely to identify you as the sender of this article. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas. You are going to email the following MRI Biomarkers for Brain Metastases in Lung Cancer Using Machine Learning Message Subject (Your Name) has forwarded a page to you from medRxiv Message Body (Your Name) thought you would like to see this page from the medRxiv website. Your Personal Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Share MRI Biomarkers for Brain Metastases in Lung Cancer Using Machine Learning Saahil Chadha , Durga V. Sritharan , Rohan Sharma , Darin Dolezal , Sampada Chande , Gregory Breuer , Daniel Fu , Arihan Gupta , Jahid Omar Hossain , Anand Srinivasan , David Weiss , Veronica L. Chiang , Don X. Nguyen , Sanjay Aneja medRxiv 2026.10.12.26365323; doi: https://doi.org/10.64898/2026.10.12.26365323 Share This Article: Copy Citation Tools MRI Biomarkers for Brain Metastases in Lung Cancer Using Machine Learning Saahil Chadha , Durga V. Sritharan , Rohan Sharma , Darin Dolezal , Sampada Chande , Gregory Breuer , Daniel Fu , Arihan Gupta , Jahid Omar Hossain , Anand Srinivasan , David Weiss , Veronica L. Chiang , Don X. Nguyen , Sanjay Aneja medRxiv 2026.10.12.26365323; doi: https://doi.org/10.64898/2026.10.12.26365323 Citation Manager Formats BibTeX Bookends EasyBib EndNote (tagged) EndNote 8 (xml) Medlars Mendeley Papers RefWorks Tagged Ref Manager RIS Zotero Tweet Widget Facebook Like Google Plus One Subject Areas All Articles Addiction Medicine (628) Allergy and Immunology (914) Anesthesia (343) Cardiovascular Medicine (4918) Dentistry and Oral Medicine (487) Dermatology (421) Emergency Medicine (666) Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1654) Epidemiology (16111) Forensic Medicine (35) Gastroenterology (1224) Genetic and Genomic Medicine (7160) Geriatric Medicine (740) Health Economics (1079) Health Informatics (5177) Health Policy (1452) Health Systems and Quality Improvement (1804) Hematology (594) HIV/AIDS (1361) Infectious Diseases (except HIV/AIDS) (16391) Intensive Care and Critical Care Medicine (1187) Medical Education (684) Medical Ethics (156) Nephrology (733) Neurology (7431) Nursing (372) Nutrition (1108) Obstetrics and Gynecology (1271) Occupational and Environmental Health (1018) Oncology (3681) Ophthalmology (1076) Orthopedics (400) Otolaryngology (460) Pain Medicine (487) Palliative Medicine (142) Pathology (714) Pediatrics (1833) Pharmacology and Therapeutics (742) Primary Care Research (780) Psychiatry and Clinical Psychology (6024) Public and Global Health (9877) Radiology and Imaging (2476) Rehabilitation Medicine and Physical Therapy (1491) Respiratory Medicine (1257) Rheumatology (653) Sexual and Reproductive Health (791) Sports Medicine (590) Surgery (790) Toxicology (109) Transplantation (313) Urology (299)
## Related Clinical Research

- [Targeted Crizotinib Therapy Extends Survival in ROS1 Lung Cancer Patient](https://medichelpline.com/clinical-feed/stat-news-4-how-a-targeted-drug-kept-one-patient-alive-15-years-but-failed-to-save-her.md)
- [Regionalization of Thoracic Surgery Linked to Increased Blood Transfusion at The Ottawa Hospital](https://medichelpline.com/clinical-feed/medrxiv-18-the-effect-of-regionalization-of-thoracic-surgery-on-blood-transfusion-at-the.md)
- [Dietary PUFA Intake, Sleep Patterns, and Lung Cancer Risk: Case-Control Findings from Southwest Ch](https://medichelpline.com/clinical-feed/plos-one-23-associations-of-dietary-polyunsaturated-fatty-acids-and-sleep-patterns-with.md)
- [Pope Leo XIV Diagnosed with Lung Adenocarcinoma: Key Insights](https://medichelpline.com/clinical-feed/medical-news-today-0-pope-leo-lung-cancer-diagnosis-what-to-know-about-lung-adenocarcinoma.md)
- [Label-free ML identifies multi-cancer signal in urine and plasma four-metabolite panel](https://medichelpline.com/clinical-feed/medrxiv-20-label-free-machine-learning-detects-a-multi-cancer-signal-in-a-noninvasive.md)

## Navigation
- [← Back to Oncology Feed](https://medichelpline.com/clinical-feed/oncology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.